Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation
1998

Understanding Camptothecin Resistance in Lung Cancer Cells

publication Evidence: moderate

Author Information

Author(s): M Sorensen, M Sehested, IJ Christensen, JK Larsen, PB Jensen

Primary Institution: Rigshospitalet, Copenhagen, Denmark

Hypothesis

Can low-level resistance to camptothecin occur without a reduction in DNA topoisomerase I or drug-induced cleavable complex formation?

Conclusion

Acquired resistance to camptothecin can occur without a decrease in topoisomerase I levels or cleavable complex formation, suggesting that reduced DNA double strand breaks may play a significant role in early resistance.

Supporting Evidence

  • NYH/CAM15 cells showed no reduction in topoisomerase I content compared to wild-type cells.
  • DNA double strand breaks were fewer in NYH/CAM15 cells than in wild-type cells after camptothecin treatment.
  • Cell cycle analysis indicated that both resistant cell lines had similar growth rates to wild-type cells.

Takeaway

Some cancer cells can become resistant to a drug called camptothecin without losing the proteins that the drug targets, which means they can still survive even when the drug is present.

Methodology

Two small-cell lung cancer cell lines were established with varying levels of resistance to camptothecin through stepwise drug exposure, and various assays were conducted to measure DNA damage and cell cycle distribution.

Limitations

The study's findings may not directly translate to clinical situations due to the high resistance indices observed in cell lines compared to what is typically seen in patients.

Statistical Information

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication